PT - JOURNAL ARTICLE AU - Hillus, David AU - Schwarz, Tatjana AU - Tober-Lau, Pinkus AU - Hastor, Hana AU - Thibeault, Charlotte AU - Kasper, Stefanie AU - Helbig, Elisa T. AU - Lippert, Lena J. AU - Tscheak, Patricia AU - Schmidt, Marie Luisa AU - Riege, Johanna AU - Solarek, André AU - Kalle, Christof von AU - Dang-Heine, Chantip AU - Kopankiewicz, Piotr AU - Suttorp, Norbert AU - Drosten, Christian AU - Bias, Harald AU - Seybold, Joachim AU - EICOV/COVIM Study Group AU - Conrad, Claudia AU - Steuer, Doris AU - Gläser, Ute AU - Sinnigen, Anne-Sophie AU - Rubisch, Carolin AU - Olk, Nadine AU - Hasler, Lisbeth AU - Sanchez-Rezza, Angela AU - Kronenberg, Paolo AU - Horn, Alexandra AU - Koch, Willi AU - Stubbemann, Paula AU - Gabelich, Julie-Anne AU - Münn, Friederike AU - Tesch, Julia AU - Mackeldanz, Petra AU - Bergfeld, Leon AU - Bleicker, Tobias AU - Beheim-Schwarzbach, Jörn Ilmo AU - Hiller, Anna AU - Brumhard, Sophia AU - Bardtke, Lara AU - Pohl, Kai AU - Wendisch, Daniel AU - Georg, Philipp AU - Treue, Denise AU - Briesemeister, Dana AU - Schlesinger, Jenny AU - Hetey, Andreas AU - Kegel, Luisa AU - Richter, Annelie AU - Al-Rim, Ben AU - Maeß, Birgit AU - Behn, Kerstin AU - Lysi, Michelle AU - Zvorc, Saskia AU - Rönnefarth, Maria AU - Schmidt, Sein AU - Krannich, Alexander AU - Schellenberger, Isabelle AU - Schwanitz, Georg AU - Schenkel, Viktoria AU - Bethke, Norma AU - Hülso, Claudia AU - Dieckmann, Sebastian AU - Peiser, Christian AU - Kurth, Florian AU - Corman, Victor Max AU - Sander, Leif Erik TI - Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study AID - 10.1101/2021.05.19.21257334 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.19.21257334 4099 - http://medrxiv.org/content/early/2021/06/02/2021.05.19.21257334.short 4100 - http://medrxiv.org/content/early/2021/06/02/2021.05.19.21257334.full AB - Objective to assess reactogenicity and immunogenicity of heterologous prime-boost immunisations of ChAdOx1-nCoV19 (Vaxzevria, ChAdOx) followed by BNT162b2 (Comirnaty, BNT) compared to homologous BNT/BNT immunisation.Design prospective, observational cohort study.Setting unicenter study in a cohort of health care workers at a tertiary care center in Berlin, Germany.Participants 340 health care workers immunised between 27 December 2020 and 21 May 2021 at Charité - Universitätsmedizin Berlin, GermanyMain outcome measures the main outcomes were reactogenicity assessed on days one, three, five and seven post prime and boost vaccination, and immunogenicity measured by serum SARS-CoV-2 full spike-, spike S1-, and spike RBD-IgG, virus neutralisation capacity, anti-S1-IgG avidity, and T cell reactivity measured by Interferon gamma release assay at 3-4 weeks post prime and boost immunisation.Results Heterologous ChAdOx/BNT booster vaccination was overall well-tolerated and reactogenicity was largely comparable to homologous BNT/BNT vaccination. Systemic reactions were most frequent after prime immunisation with ChAdOx (86%, 95CI: 79-91), and less frequent after homologous BNT/BNT (65%, 95CI: 56-72), or heterologous ChAdOx/BNT booster vaccination (48%, 95CI: 36-59). Serum antibody responses and T cell reactivity were strongly increased after both homologous and heterologous boost, and immunogenicity was overall robust, and comparable between both regimens in this cohort, with slightly increased S1-IgG avidity and T cell responses following heterologous booster immunisation.Conclusions Evidence of rare thrombotic events associated with ChAdOx has led to recommendation of a heterologous booster with mRNA vaccines for certain age groups in several European countries, despite a lack of robust safety and immunogenicity data for this vaccine regimen. This interim analysis provides evidence that the currently recommended heterologous ChAdOx/BNT immunisation regimen with 10-12 week vaccine intervals is well tolerated and slightly more immunogenic compared to homologous BNT/BNT vaccination with three week vaccine intervals. Heterologous prime-boost immunisation for COVID-19 may be generally applicable to optimise logistics and improve immunogenicity and to mitigate potential intermittent supply shortages for individual vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT-No. 2021-001512-28Funding StatementSupported by the German Federal Ministry of Education and Research (BMBF) Forschungsnetzwerk der Universitaetsmedizin zu Covid-19 COVIM - FKZ: 01KX2021 (to L.E.S., V.M.C., F.K., C.D., N.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EICOV was approved by the ethics committee (IRB) of Charite - Universitaetsmedizin Berlin (EA4/245/20) and COVIM (EudraCT-No. 2021-001512-28) was approved by the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) and by the Ethics committee of the state of Berlin.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request.